001463376 000__ 06147cam\a22006017i\4500
001463376 001__ 1463376
001463376 003__ OCoLC
001463376 005__ 20230601003318.0
001463376 006__ m\\\\\o\\d\\\\\\\\
001463376 007__ cr\cn\nnnunnun
001463376 008__ 230421s2023\\\\sz\a\\\\o\\\\\001\0\eng\d
001463376 019__ $$a1376176426
001463376 020__ $$a9783031205378$$qelectronic book
001463376 020__ $$a3031205375$$qelectronic book
001463376 020__ $$z9783031205361
001463376 020__ $$z3031205367
001463376 0247_ $$a10.1007/978-3-031-20537-8$$2doi
001463376 035__ $$aSP(OCoLC)1376791202
001463376 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dYDX$$dUKAHL$$dYDX
001463376 049__ $$aISEA
001463376 050_4 $$aRS199.5$$b.V57 2023
001463376 08204 $$a615/.6$$223/eng/20230421
001463376 24500 $$aViral drug delivery systems :$$badvances in treatment of infectious diseases /$$cRanjita Shegokar, Yashwant Pathak, editors.
001463376 264_1 $$aCham :$$bSpringer,$$c2023.
001463376 300__ $$a1 online resource (292 pages) :$$billustrations (black and white, and color).
001463376 336__ $$atext$$btxt$$2rdacontent
001463376 337__ $$acomputer$$bc$$2rdamedia
001463376 338__ $$aonline resource$$bcr$$2rdacarrier
001463376 500__ $$aIncludes index.
001463376 5050_ $$aGlobal health and Viral diseases past, present and Future -- Drug resistance and statistics and patent status -- cellular understanding viral diseases -- Viral: current treatment options -- Mucosal drug delivery strategies for antiviral intervention -- Micro, nano emulsions in viral -- Novel formulation approaches to treat Ebola- virus -- Ebola- drug delivery -- Polymers for Bio sensing Applications in antiviral therapy and diagnosis -- Nanotechnology: A Stepping Stone towards Viral Hepatitis Treatment and Prevention in Children -- Recent Developments in the Treatment of Influenza -- Covid 19: from molecular pathogenesis to potential repurposed treatments -- Nano drug delivery systems for Covid-19-drug delivery -- Exploring the link between malaria and Covid 19 -- Characterization of biofunctionalized nanoparticles in ID -- Covid- azithromycin-ritonavir -- Strategies to combat Covid-19 drug delivery -- Phytomolecules and NDDS Covid-19.
001463376 506__ $$aAccess limited to authorized users.
001463376 520__ $$aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems The third volume of series is focused on viral drug delivery systems. Typically, virus attaches to the cells (referred as host cell) and releases its DNA or RNA inside the cell. In second stage, viruss genetic material takes control of the cell and forces it to replicate the virus leading to onset of disease symptoms. DNA class of viruses include Herpes, Papilloma and Adeno viruses. RNA class of viruses include retroviruses, such as HIV immunodeficiency virus and SARS COV 2 / Corona virus. This book addresses recent developments in viral drug delivery systems. It covers many different aspects of viral infections, ways to treat them using modern drug delivery systems like nano particulate carriers. The choice of viral delivery systems mainly depends upon the type of virus, duration of life cycle, presence of drug resistance, cellular and mucosal interaction of virus, accordingly gene or non-gene drug delivery systems are selected. Besides that, this book also reports global dynamics of viral diseases, future predictions of infection rate, current treatment options, details of drug carriers like nanoemulsions, polymeric nanoparticles, role of biofunctionalization, and phyto-molecules in treatment of viral infections particularly herpes, Covid-19, Ebola, HIV/AIDS, influenza and viral hepatitis. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of viral drug delivery research.
001463376 588__ $$aDescription based on print version record.
001463376 650_0 $$aVirus diseases$$xChemotherapy.
001463376 650_0 $$aDrug delivery systems.
001463376 655_0 $$aElectronic books.
001463376 7001_ $$aShegokar, Ranjita,$$eeditor.
001463376 7001_ $$aPathak, Yashwant,$$eeditor.$$1https://isni.org/isni/0000000116715199
001463376 77608 $$iPrint version:$$tViral drug delivery systems.$$dCham : Springer, 2023$$z9783031205361$$w(OCoLC)1371813343
001463376 852__ $$bebk
001463376 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-20537-8$$zOnline Access$$91397441.1
001463376 909CO $$ooai:library.usi.edu:1463376$$pGLOBAL_SET
001463376 980__ $$aBIB
001463376 980__ $$aEBOOK
001463376 982__ $$aEbook
001463376 983__ $$aOnline
001463376 994__ $$a92$$bISE